GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Stock Based Compensation

Fusion Antibodies (LSE:FAB) Stock Based Compensation : £0.02 Mil (TTM As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Stock Based Compensation?

Fusion Antibodies's Stock Based Compensation for the six months ended in Sep. 2023 was £0.02 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2023 was £0.02 Mil.


Fusion Antibodies Stock Based Compensation Historical Data

The historical data trend for Fusion Antibodies's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Stock Based Compensation Chart

Fusion Antibodies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only 0.10 0.08 0.02 0.02 0.04

Fusion Antibodies Semi-Annual Data
Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.01 - - 0.02

Fusion Antibodies Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £0.02 Mil.


Fusion Antibodies Stock Based Compensation Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's Stock Based Compensation provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusion Antibodies (LSE:FAB) Business Description

Traded in Other Exchanges
N/A
Address
1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 10-21-2022